Novartis submits Exjade iron chelator
This article was originally published in Pharmaceutical Approvals Monthly
Novartis submits its iron chelator Exjade (deferasirox, formerly ICL670) May 3 for treatment of chronic iron overload due to blood transfusions. The firm is touting the agent's once-daily dosing and oral route of administration as advantages over standard treatment, which requires a daily infusion that can take several hours. Novartis markets another iron chelating agent, Desferal (deferoxamine), which is administered via transfusion. The company reported during its Jan. 20 R&D update that Exjade missed its primary endpoint of non-inferiority to Desferal in a pivotal study, noting that the finding could impact timing or labeling (1Pharmaceutical Approvals Monthly February 2005, p. 3). The NDA was submitted within the firm's projected first-half 2005 timeframe...
You may also be interested in...
Novartis plans three NME filings in 2005, including first oral VEGF agent, firm says during Jan. 20 R&D day. PTK787 has blockbuster potential in colorectal cancer, Novartis says. Nine more NME filings are scheduled for next two years
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.